Company Filing History:
Years Active: 2019
Title: Innovator Spotlight: Paul Heffner Slagle
Introduction: Paul Heffner Slagle is a notable inventor based in Seattle, Washington. With a significant contribution to the field of biotechnology, Slagle has made advancements that have the potential to impact therapeutic treatments.
Latest Patents: Slagle holds a patent for "Antibody Derivatives." This groundbreaking invention relates to a bivalent, bispecific construct that comprises an anti-IL-6 antibody, or a derivative thereof, and an anti-IL-23 antibody, or a derivative thereof. The patent outlines the use of these constructs in therapy, emphasizing the therapeutic potential of innovative anti-IL-6 and anti-IL-23 antibodies.
Career Highlights: Currently, Slagle is employed at MedImmune Limited, where he utilizes his expertise in the development of biopharmaceuticals. His work at MedImmune contributes to advancing medical treatments that address complex diseases.
Collaborations: Slagle has collaborated with distinguished colleagues, including Kenneth H. Grabstein and William Brady. Together, they have fostered a rich environment for innovation, enhancing the capabilities of their research and development efforts.
Conclusion: Paul Heffner Slagle represents a passionate inventor whose contributions to antibody technology hold promise for future therapeutic applications. His work at MedImmune Limited and collaborations with esteemed colleagues exemplify the spirit of innovation that drives advancements in the field of biotechnology.